cyproterone acetate - medicine shortage information

Back to ALL shortages and discontinuations    Back to CRITICAL shortages and discontinuations

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.

More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub

Product details Supply Impact Dates Further Details
CYPROTERONE SANDOZ cyproterone acetate 50 mg tablet bottle
AUST R: 107330
Active ingredients:
cyproterone acetate

Dosage form:
Tablet, uncoated

Sponsor:
Sandoz Pty Ltd

Phone:
1800726369

From
26 Mar 2021
to
14 May 2021

Shortage status:
Resolved

Availability:
Available

Reason:
Other

DIANE-35 ED tablet blister pack
AUST R: 33647
Active ingredients:
cyproterone acetate
ethinylestradiol

Dosage form:
Tablet, sugar coated

Sponsor:
Bayer Australia Ltd

Phone:
1800 008 757

From
01 Apr 2021
to
15 May 2021

Shortage status:
Resolved

Availability:
Available

Reason:
Manufacturing

JULIET-35 ED tablet blister pack
AUST R: 75554
Active ingredients:
cyproterone acetate
ethinylestradiol

Dosage form:
Tablet, sugar coated

Sponsor:
Bayer Australia Ltd

Phone:
1800008757

From
01 Apr 2021
to
15 May 2021

Shortage status:
Resolved

Availability:
Available

Reason:
Manufacturing

APO-CYPROTERONE ACETATE cyproterone acetate 100mg tablet blister pack
AUST R: 101535
Active ingredients:
cyproterone acetate

Dosage form:
Tablet, uncoated

Sponsor:
Apotex Pty Ltd

Phone:
02 8877 8333

Deletion from market:
15 Nov 2020

Shortage status:
Discontinued

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

CYPROSTAT cyproterone acetate 50mg tablet blister pack
AUST R: 156921
Active ingredients:
cyproterone acetate

Dosage form:
Tablet, uncoated

Sponsor:
Bayer Australia Ltd

Phone:
1800 008 757

Deletion from market:
01 Oct 2020

Shortage status:
Discontinued

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability